These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 9356046)

  • 1. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts.
    Jaeger C; Brendel MD; Hering BJ; Eckhard M; Bretzel RG
    Diabetes; 1997 Nov; 46(11):1907-10. PubMed ID: 9356046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression.
    Jaeger C; Hering BJ; Hatziagelaki E; Federlin K; Bretzel RG
    J Mol Med (Berl); 1999 Jan; 77(1):45-8. PubMed ID: 9930926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Islet cell antibodies and glutamic acid decarboxylase antibodies in patients with insulin-dependent diabetes mellitus undergoing kidney and islet-after-kidney transplantation.
    Jaeger C; Hering BJ; Dyrberg T; Federlin K; Bretzel RG
    Transplantation; 1996 Aug; 62(3):424-6. PubMed ID: 8779696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of diabetes-associated autoantibodies after sequential intraportal islet allograft associated with kidney transplantation in type 1 diabetes.
    Vantyghem MC; Fajardy I; Pigny P; Noel C; Kerr-Conte J; Gmyr V; Vandewalle B; Proye C; Pattou F
    Diabetes Metab; 2003 Dec; 29(6):595-601. PubMed ID: 14707888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft.
    Keymeulen B; Ling Z; Gorus FK; Delvaux G; Bouwens L; Grupping A; Hendrieckx C; Pipeleers-Marichal M; Van Schravendijk C; Salmela K; Pipeleers DG
    Diabetologia; 1998 Apr; 41(4):452-9. PubMed ID: 9562350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes.
    Braghi S; Bonifacio E; Secchi A; Di Carlo V; Pozza G; Bosi E
    Diabetes; 2000 Feb; 49(2):218-24. PubMed ID: 10868938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation.
    Thivolet C; Abou-Amara S; Martin X; Lefrancois N; Petruzzo P; McGregor B; Bosshard S; Dubernard JM
    Transplantation; 2000 Jan; 69(1):99-103. PubMed ID: 10653387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine-phosphatase and glutamate-decarboxylase antibodies after simultaneous pancreas kidney transplantation: do they have an impact on pancreas graft survival?
    Rodelo-Haad C; Aguera ML; Martinez-Vaquera S; Pendon-Ruiz de Mier MV; Salmeron-Rodriguez MD; Esquivias E; Navarro MD; Rodriguez-Benot A; Aljama P
    Transplant Proc; 2015; 47(1):107-11. PubMed ID: 25645784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice.
    Okitsu T; Bartlett ST; Hadley GA; Drachenberg CB; Farney AC
    Am J Transplant; 2001 Jul; 1(2):138-45. PubMed ID: 12099361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of autoimmune islet allograft destruction by engraftment of donor T cells.
    Bartlett ST; Schweitzer EJ; Kuo PC; Johnson LB; Delatorre A; Hadley GA
    Transplantation; 1997 Jan; 63(2):299-303. PubMed ID: 9020334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation.
    Roelen DL; Huurman VA; Hilbrands R; Gillard P; Duinkerken G; van der Meer-Prins PW; Versteeg-van der Voort Maarschalk MF; Mathieu C; Keymeulen B; Pipeleers DG; Roep BO; Claas FH
    Clin Exp Immunol; 2009 Apr; 156(1):141-8. PubMed ID: 19161445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients.
    Roep BO; Stobbe I; Duinkerken G; van Rood JJ; Lernmark A; Keymeulen B; Pipeleers D; Claas FH; de Vries RR
    Diabetes; 1999 Mar; 48(3):484-90. PubMed ID: 10078547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syngeneic islet transplantation in prediabetic BB-DP rats--a synchronized model for studying beta-cell destruction during the development of IDDM.
    Christensen UB; Sparre T; Cooke A; Andersen HU; Mandrup-Poulsen T; Nerup J
    Autoimmunity; 1998; 28(2):91-107. PubMed ID: 9771979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of a broad repertoire of GAD65-specific T-cells in type 1 diabetes patients with graft dysfunction after allogeneic islet transplantation.
    Chujo D; Foucat E; Takita M; Itoh T; Sugimoto K; Shimoda M; Yagi K; Yamagishi M; Tamura Y; Yu L; Naziruddin B; Levy MF; Ueno H; Matsumoto S
    Cell Transplant; 2012; 21(12):2783-95. PubMed ID: 22963904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity.
    Bonifacio E; Genovese S; Braghi S; Bazzigaluppi E; Lampasona V; Bingley PJ; Rogge L; Pastore MR; Bognetti E; Bottazzo GF
    Diabetologia; 1995 Jul; 38(7):816-22. PubMed ID: 7556984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Operational immune tolerance towards transplanted allogeneic pancreatic islets in mice and a non-human primate.
    Abdulreda MH; Berman DM; Shishido A; Martin C; Hossameldin M; Tschiggfrie A; Hernandez LF; Hernandez A; Ricordi C; Parel JM; Jankowska-Gan E; Burlingham WJ; Arrieta-Quintero EA; Perez VL; Kenyon NS; Berggren PO
    Diabetologia; 2019 May; 62(5):811-821. PubMed ID: 30701283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity.
    Christie MR; Genovese S; Cassidy D; Bosi E; Brown TJ; Lai M; Bonifacio E; Bottazzo GF
    Diabetes; 1994 Oct; 43(10):1254-9. PubMed ID: 7926297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody response to islet transplantation in type 1 diabetes.
    Bosi E; Braghi S; Maffi P; Scirpoli M; Bertuzzi F; Pozza G; Secchi A; Bonifacio E
    Diabetes; 2001 Nov; 50(11):2464-71. PubMed ID: 11679423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade.
    Makhlouf L; Kishimoto K; Smith RN; Abdi R; Koulmanda M; Winn HJ; Auchincloss H; Sayegh MH
    Diabetes; 2002 Nov; 51(11):3202-10. PubMed ID: 12401711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test.
    Wiest-Ladenburger U; Hartmann R; Hartmann U; Berling K; Böhm BO; Richter W
    Diabetes; 1997 Apr; 46(4):565-71. PubMed ID: 9075795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.